P2Y1 antagonists:: Combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring

被引:32
作者
Costanzi, Stefano [1 ]
Tikhonova, Irina G.
Ohno, Michihiro
Roh, Eun Joo
Joshi, Bhalchandra V.
Colson, Anny-Odile
Houston, Dayle
Maddileti, Savitri
Harden, T. Kendall
Jacobson, Kenneth A.
机构
[1] NIDDK, Lab Biol Modeling, NIH, Bethesda, MD 20892 USA
[2] NIDDK, Mol Recognit Sect, NIH, Bethesda, MD 20892 USA
[3] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27515 USA
关键词
D O I
10.1021/jm0700971
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
P2Y(1) is an ADP-activated G protein-coupled receptor (GPCR). Its antagonists impede platelet aggregation in vivo and are potential antithrombotic agents. Combining ligand and structure-based modeling we generated a consensus model (LIST-CM) correlating antagonist structures with their potencies. We docked 45 antagonists into our rhodopsin-based human P2Y(1) homology model and calculated docking scores and free binding energies with the Linear Interaction Energy (LIE) method in continuum-solvent. The resulting alignment was also used to build QSAR based on CoMFA, CoMSIA, and molecular descriptors. To benefit from the strength of each technique and compensate for their limitations, we generated our LIST-CM with a PLS regression based on the predictions of each methodology. A test set featuring untested substituents was synthesized and assayed in inhibition of 2-MeSADP-stimulated PLC activity and in radioligand binding. LIST-CM outperformed internal and external predictivity of any individual model to predict accurately the potency of 75% of the test set.
引用
收藏
页码:3229 / 3241
页数:13
相关论文
共 42 条
[1]   International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy [J].
Abbracchio, Maria P. ;
Burnstock, Geoffrey ;
Boeynaems, Jean-Marie ;
Barnard, Eric A. ;
Boyer, Jose L. ;
Kennedy, Charles ;
Knight, Gillian E. ;
Fumagalli, Marta ;
Gachet, Christian ;
Jacobson, Kenneth A. ;
Weisman, Gary A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :281-341
[2]   NEW METHOD FOR PREDICTING BINDING-AFFINITY IN COMPUTER-AIDED DRUG DESIGN [J].
AQVIST, J ;
MEDINA, C ;
SAMUELSSON, JE .
PROTEIN ENGINEERING, 1994, 7 (03) :385-391
[3]  
Boyer JL, 1996, MOL PHARMACOL, V50, P1323
[4]  
BOYER JL, 1989, J BIOL CHEM, V264, P884
[5]   Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors [J].
Camaioni, E ;
Boyer, JL ;
Mohanram, A ;
Harden, TK ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (02) :183-190
[6]   Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor [J].
Cattaneo, M ;
Lecchi, A ;
Ohno, M ;
Joshi, LV ;
Besada, P ;
Tchilibon, S ;
Lombardi, R ;
Bischofberger, N ;
Harden, TK ;
Jacobson, KA .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (10) :1995-2002
[7]   AN INTERNAL COORDINATE MONTE-CARLO METHOD FOR SEARCHING CONFORMATIONAL SPACE [J].
CHANG, G ;
GUIDA, WC ;
STILL, WC .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (12) :4379-4386
[8]  
*CHEM COMP GROUP I, 2005, MOE 2005 06
[9]   Human P2Y6 receptor:: Molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference [J].
Costanzi, S ;
Joshi, BV ;
Maddileti, S ;
Mamedova, L ;
Gonzalez-Moa, MJ ;
Marquez, VE ;
Harden, TK ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (26) :8108-8111
[10]   Architecture of P2Y nucleotide receptors: Structural comparison based on sequence analysis, mutagenesis, and homology modeling [J].
Costanzi, S ;
Mamedova, L ;
Gao, ZG ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (22) :5393-5404